New combo aims to tame hairy cell leukemia with fewer side effects
Disease control
Completed
This study tested a combination of two drugs—vemurafenib (taken by mouth) and rituximab (given by IV)—in 15 people with hairy cell leukemia, a rare blood cancer. The goal was to see if this treatment works as well as or better than standard chemotherapy, but with fewer side effec…
Phase: PHASE2 • Sponsor: Scripps Health • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC